Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Robinhood Markets, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Robinhood Markets, Inc. trades at $114.03 (market cap $101.85B). The key difference: Robinhood Markets, Inc. is far larger — about 12.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | HOOD | |
|---|---|---|
Market Cap | $8.04B | $101.85B |
Sector | Health | Technology |
52-Week High | $339.75 | $152.46 |
52-Week Low | $241.71 | $65.16 |
Enterprise Value | $7.85B | $103.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Robinhood (HOOD) trades at $109.86, down 1.88% today, with strong technical momentum showing bullish moving averages and key support at $108. Fundamentally, the company demonstrates robust growth with 2025 revenue reaching $4.47 billion and net income of $1.88 billion, though valuation metrics remain elevated with a P/E of 53.33. Recent earnings show mixed results with a Q1 2026 miss but positive Q3 and Q4 2025 beats. The company's Robinhood Chain launch and potential asset-backed securities offering represent significant growth initiatives.
The outlook remains positive with analyst consensus at Buy (73% rating) and a $112.07 price target suggesting modest upside. Key opportunities include continued revenue diversification beyond crypto and new product offerings. Primary risks include valuation concerns, crypto market volatility exposure, and competitive pressures in the brokerage space. Operating cash flow improvement to $1.64 billion in 2025 provides financial stability for growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
